MedTrace Logo

Study on the Staging and Prognosis Model of Bladder Cancer

NCT06565923 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-08-22

No results posted yet for this study

Summary

Firstly, we retrospectively gathered the patient information who compliant with the criteria from 2012 to 2023, encompassing basic information, clinical information, along with MRI images, blood/urine samples, and tissue samples, for conducting relevant analyses of radiomics. Subsequently, based on artificial intelligence technology, deep learning and machine learning models were established on the basis of MRI radiomics and pathological histomics. Ultimately, the following research aims were accomplished: 1. Primary research objective: To explore the role of artificial intelligence and multimodal omics features in the staging and prognosis monitoring of bladder cancer. 2. Secondary objective: To explore the correlations among radiomics, case histomics, and test omics.

Conditions

Sponsors & Collaborators

  • Suzhou Municipal Hospital

    collaborator OTHER

  • Yixing People's Hospital

    collaborator OTHER

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER

  • Huai an First People Hospital

    collaborator UNKNOWN

  • Jiangsu Province Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • The second affiliated hospital of Xuzhou medical university

    collaborator UNKNOWN

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-18
Primary Completion
2025-07-18
Completion
2025-07-18

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06565923 on ClinicalTrials.gov